The trajectory of companies tied to the drug's history presents a intricate investment scenario . While the initial success generated substantial returns , generic copies have significantly impacted revenue. Investing in associated pharmaceutical firms now requires a discerning assessment of patent protection , evolving medical changes, and the pot